THE SCIENCE
Semax is a synthetic heptapeptide consisting of the ACTH(4–7) sequence with a Pro-Gly-Pro (PGP) extension. Research has investigated Semax in relation to neurobiology, cognitive processes, neuroprotective activity, and regulation of neurotrophic and cellular signaling pathways.
MOLECULAR STRUCTURE
Semax is composed of the sequence Met-Glu-His-Phe-Pro-Gly-Pro and incorporates the ACTH(4–7) fragment together with the Pro-Gly-Pro sequence. This structure has been investigated in experimental research examining the peptide's effects on neuronal and neurotrophic signaling.
BDNF & NEUROTROPHIN SIGNALING
Research has investigated Semax in relation to brain-derived neurotrophic factor (BDNF) and other neurotrophins. Experimental studies in rats have reported increases in BDNF protein and changes in BDNF and TrkB expression following Semax administration, particularly in brain regions involved in learning and memory. PubMed
COGNITIVE & MEMORY RESEARCH
Experimental research has examined Semax in relation to learning, memory, and attention. Studies in animal models have reported changes in conditioned-learning responses following Semax administration, while human research has also investigated its effects under specific clinical and experimental conditions.
NEUROPROTECTIVE RESEARCH
Semax has been investigated in experimental models of neurological injury, including cerebral ischemia. Research has examined changes in gene and protein expression associated with inflammation, cellular stress, neuronal signaling, and recovery following ischemic injury.
NEUROIMMUNE & CELLULAR SIGNALING
- Experimental studies have investigated Semax in relation to neuroimmune signaling and changes in gene expression following cerebral ischemia. Research has identified effects involving immune-response genes, inflammatory pathways, neurotransmitter-related genes, and cellular stress responses, although the precise mechanisms remain an active area of investigation.
RESEARCH LIMITATIONS
The evidence base for Semax includes both human research and substantial preclinical research, particularly involving animal models of neurological injury and neurotrophic signaling. Findings should be interpreted according to the study population, experimental model, formulation, route of administration, and specific endpoints measured, and preclinical findings should not automatically be assumed to demonstrate the same effects in humans.